[1] 刘倩, 陈佩娟.  肿瘤放疗联合免疫治疗的发展现状和前景[J]. 现代肿瘤医学, 2017, 25(8): 1325-1328.   doi: 10.3969/j.issn.1672-4992.2017.08.042
Liu Q, Chen PJ.  The current status and future of radiotherapy and immunotherapy and its combination in treatment of cancer[J]. Mod Oncol, 2017, 25(8): 1325-1328.   doi: 10.3969/j.issn.1672-4992.2017.08.042
[2] Dhiman VK, Bolt MJ, White KP.  Nuclear receptors in cancer — uncovering new and evolving roles through genomic analysis[J]. Nat Rev Genet, 2018, 19(3): 160-174.   doi: 10.1038/nrg.2017.102
[3] Long MD, Campbell MJ.  Pan-cancer analyses of the nuclear receptor superfamily[J]. Nucl Receptor Res, 2015, 2: 101182-.   doi: 10.11131/2015/101182
[4] Pietri E, Massa I, Bravaccini S, et al.  Phase Ⅱ study of dehydroepiandrosterone in androgen receptor-positive metastatic breast cancer[J]. Oncologist, 2019, 24(6): 743-744, e198−e205.   doi: 10.1634/theoncologist.2018-0243
[5] Mahalingam D, Wang JS, Hamilton EP, et al.  Phase 1 open-label, multicenter study of first-in-class RORγ agonist LYC-55716 (cintirorgon): safety, tolerability, and preliminary evidence of antitumor activity[J]. Clin Cancer Res, 2019, 25(12): 3508-3516.   doi: 10.1158/1078-0432.CCR-18-3185
[6] Zhao LJ, Hu HB, Gustafsson JÅ, et al.  Nuclear receptors in cancer inflammation and immunity[J]. Trends Immunol, 2020, 41(2): 172-185.   doi: 10.1016/j.it.2019.12.006
[7] Taghizadeh B, Ghavami L, Nikoofar A, et al.  Equol as a potent radiosensitizer in estrogen receptor-positive and -negative human breast cancer cell lines[J]. Breast Cancer, 2015, 22(4): 382-390.   doi: 10.1007/s12282-013-0492-0
[8]

Zhang WH, Liao CY, Chtatou H, et al. Apalutamide sensitizes prostate cancer to ionizing radiation via inhibition of non-homologous end-joining DNA repair[J/OL]. Cancers (Basel), 2019, 11(10): 1593[2021-02-19]. https://www.mdpi.com/2072-6694/11/10/1593. DOI: 10.3390/cancers11101593.
[9] Xue J, Zhu W, Song J, et al.  Activation of PPARα by clofibrate sensitizes pancreatic cancer cells to radiation through the Wnt/β-catenin pathway[J]. Oncogene, 2018, 37(7): 953-962.   doi: 10.1038/onc.2017.401
[10] Liang HZ, Shen XL.  LXR activation radiosensitizes non-small cell lung cancer by restricting myeloid-derived suppressor cells[J]. Biochem Biophys Res Commun, 2020, 528(2): 330-335.   doi: 10.1016/j.bbrc.2020.04.137
[11] Mangelsdorf DJ, Thummel C, Beato M, et al.  The nuclear receptor superfamily: the second decade[J]. Cell, 1995, 83(6): 835-839.   doi: 10.1016/0092-8674(95)90199-x
[12] Rathkopf DE, Morris MJ, Fox JJ, et al.  Phase Ⅰ study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer[J]. J Clin Oncol, 2013, 31(28): 3525-3530.   doi: 10.1200/JCO.2013.50.1684
[13] Komatsu Y, Yoshino T, Yamazaki K, et al.  Phase Ⅰ study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer[J]. Invest New Drugs, 2014, 32(3): 473-480.   doi: 10.1007/s10637-013-0056-3
[14] Bergh J, Jönsson PE, Lidbrink EK, et al.  FACT: an open-label randomized phase Ⅲ study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer[J]. J Clin Oncol, 2012, 30(16): 1919-1925.   doi: 10.1200/JCO.2011.38.1095
[15] Wang J, Yang QF, Haffty BG, et al.  Fulvestrant radiosensitizes human estrogen receptor-positive breast cancer cells[J]. Biochem Biophys Res Commun, 2013, 431(2): 146-151.   doi: 10.1016/j.bbrc.2013.01.006
[16] Paximadis P, Najy AJ, Snyder M, et al.  The interaction between androgen receptor and PDGF-D in the radiation response of prostate carcinoma[J]. Prostate, 2016, 76(6): 534-542.   doi: 10.1002/pros.23135
[17]

Speers C, Zhao SG, Chandler B, et al. Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer[J/OL]. NPJ Breast Cancer, 2017, 3: 29[2021-02-19]. https://www.nature.com/articles/s41523-017-0038-2. DOI: 10.1038/s41523-017-0038-2.
[18]

Chou FJ, Chen Y, Chen D, et al. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression[J/OL]. EBioMedicine, 2019, 40: 504−516[2021-02-19]. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(18)30627-3/fulltext. DOI: 10.1016/j.ebiom.2018.12.050.
[19]

Michmerhuizen AR, Chandler B, Olsen E, et al. Seviteronel, a novel CYP17 lyase inhibitor and androgen receptor antagonist, radiosensitizes AR-positive triple negative breast cancer cells[J/OL]. Front Endocrinol (Lausanne), 2020, 11: 35[2021-02-19]. https://www.frontiersin.org/articles/10.3389/fendo.2020.00035/full. DOI: 10.3389/fendo.2020.00035.
[20] Song JY, Shen WH, Xue J, et al.  Fenofibrate enhances the radiosensitivity of human pancreatic cancer cells in vitro and in vivo[J]. Int J Clin Exp Med, 2017, 10(11): 15168-15177.
[21] Benedetti E, D'Angelo M, Ammazzalorso A, et al.  PPARα antagonist AA452 triggers metabolic reprogramming and increases sensitivity to radiation therapy in human glioblastoma primary cells[J]. J Cell Physiol, 2017, 232(6): 1458-1466.   doi: 10.1002/jcp.25648
[22]

Kaur S, Nag A, Gangenahalli G, et al. Peroxisome proliferator activated receptor gamma sensitizes non-small cell lung carcinoma to Gamma irradiation induced apoptosis[J/OL]. Front Genet, 2019, 10: 554[2021-02-19]. https://www.frontiersin.org/articles/10.3389/fgene.2019.00554/full. DOI: 10.3389/fgene.2019.00554.
[23] Han EJ, Im CN, Park SH, et al.  Combined treatment with peroxisome proliferator-activated receptor (PPAR) gamma ligands and gamma radiation induces apoptosis by PPARγ-independent up-regulation of reactive oxygen species-induced deoxyribonucleic acid damage signals in non-small cell lung cancer cells[J]. Int J Radiat Oncol Biol Phys, 2013, 85(5): e239-e248.   doi: 10.1016/j.ijrobp.2012.11.040
[24] An ZZ, Muthusami S, Yu JR, et al.  T0070907, a PPAR γ inhibitor, induced G2/M arrest enhances the effect of radiation in human cervical cancer cells through mitotic catastrophe[J]. Reprod Sci, 2014, 21(11): 1352-1361.   doi: 10.1177/1933719114525265
[25] Ryu S, Stein JP, Chung CT, et al.  Enhanced apoptosis and radiosensitization by combined 13-cis-retinoic acid and interferon-α2a; role of RAR-β gene[J]. Int J Radiat Oncol Biol Phys, 2001, 51(3): 785-790.   doi: 10.1016/s0360-3016(01)01718-7
[26] Ray J, Haughey C, Hoey C, et al.  miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA[J]. Cancer Lett, 2020, 31(473): 107-117.   doi: 10.1016/j.canlet.2019.12.025
[27] Tabraue C, Lara PC, De Mirecki-Garrido M, et al.  LXR signaling regulates macrophage survival and inflammation in response to ionizing radiation[J]. Int J Radiat Oncol Biol Phys, 2019, 104(4): 913-923.   doi: 10.1016/j.ijrobp.2019.03.028
[28] 赵谊宁, 陶陶, 张力杰, 等.  雌激素受体ERα及ERβ与肿瘤关系的研究进展[J]. 东南大学学报: 医学版, 2016, 35(3): 418-422.   doi: 10.3969/j.issn.1671-6264.2016.03.028
Zhao YN, Tao T, Zhang LJ, et al.  Research progress on the relationship between estrogen receptor ERα and ERβ and tumor[J]. J Southeast Univ (Med Sci Ed), 2016, 35(3): 418-422.   doi: 10.3969/j.issn.1671-6264.2016.03.028
[29] Gonzalez TL, Hancock M, Sun SQ, et al.  Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer[J]. Breast Cancer Res Treat, 2020, 180(3): 611-622.   doi: 10.1007/s10549-020-05564-y
[30] Davis R, Jia DW, Cinar B, et al.  Functional androgen receptor confers sensitization of androgen-independent prostate cancer cells to anticancer therapy via caspase activation[J]. Biochem Biophys Res Commun, 2003, 309(4): 937-945.   doi: 10.1016/j.bbrc.2003.08.096
[31] Issemann I, Green S.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators[J]. Nature, 1990, 347(6294): 645-650.   doi: 10.1038/347645a0
[32] 高菲.  PPARγ受体与消化道肿瘤相关性的研究进展[J]. 微生物学免疫学进展, 2016, 44(2): 79-83.   doi: 10.13309/j.cnki.pmi.2016.02.015
Gao F.  Progress of correlation between PPARγ receptor and digestive tract tumor[J]. Prog Microbiol Immunol, 2016, 44(2): 79-83.   doi: 10.13309/j.cnki.pmi.2016.02.015
[33] Cho YM, Yang AH, Kim BY, et al.  The cleavage fragment of retinoid X receptor-alpha ligand binding domain inhibits radiosensitization by retinoic acid[J]. Oncol Rep, 2010, 23(6): 1715-1720.   doi: 10.3892/or_00000816
[34] 李新.  维甲酸受体β功能及其与肿瘤的相关性[J]. 武警后勤学院学报: 医学版, 2014, 23(10): 867-870.   doi: 10.3969/j.issn.2095-3720.2014.10.025
Li X.  Function and relevance with tumor of RAR-β[J]. J Logistics Univ PAPF (Med Sci Ed), 2014, 23(10): 867-870.   doi: 10.3969/j.issn.2095-3720.2014.10.025
[35] Zhang XK, Zhou H, Su Y.  Targeting truncated RXRα for cancer therapy[J]. Acta Biochim Biophys Sin (Shanghai), 2016, 48(1): 49-59.   doi: 10.1093/abbs/gmv104